Several in vitro chemosensitivity tests have been developed to predict the chemotherapeutic response of tumours prior to initiation of individualized treatment for breast cancer. This study investigated whether the in vitro chemosensitivity response of cell lines derived from breast cancer patients was affected by HER2/neu expression. We cultured breast cancer cell lines from 50 patients and the adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was performed with 5-fluorouracil, gemcitabine, docetaxel, doxorubicin, methotrexate, vinorelbine and paclitaxel. 5-Fluorouracil combined a high median cell death rate (32.4%) with the narrowest range of cytotoxic effects (7.3 − 65.7%). In addition, gemcitabine showed significantly greater activity in HER2/neu-positive patients. In contrast, docetaxel was significantly less effective in HER2/neu-positive patients. No significant correlation was found between the other agents and HER2/neu expression. The use of the ATP-CRA test for metastatic tissue from patients with recurrent disease might be a useful approach to determine the most effective chemotherapy regimen.
SargentJElgieATaylorCG: The identification of drug resistance in ovarian cancer and breast cancer: Application of the MTT assay. Contrib Gynecol Obstet1994; 19: 64–75.
2.
WilsonJKSargentJMElgieAW: A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy. Br J Cancer1990; 62: 189–194.
3.
FossatiRConfalonieriCTorriV: Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women. J Clin Oncol1998; 16: 3439–3460.
4.
SjostromJBlomqvistCMouridsenH: Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: A randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer1999; 35: 1194–1201.
5.
OrrJWJrOrrPKernDH: Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. Cancer J Sci Am1999; 5: 174–178.
6.
AllredDCClarkGMTandonAK: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol1992; 10: 599–605.
7.
GustersonBAGelberRDGoldhirschA: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol1992; 10: 1049–1056.
8.
WeisenthalLMKernDH: Prediction of drug resistance in cancer chemotherapy: The Kern and DiSC assays. Oncology (Williston Park)1991; 5: 93–103; discussion 4, 11–14, 17–18.
9.
CortazarPJohnsonBE: Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol1999; 17: 1625–1631.
10.
KangSMParkMSChangJ: A feasibility study of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) as a chemosensitivity test for lung cancer. Cancer Treat Res2005; 37: 223–227.
11.
FisherBBrownAMDimitrovNV: Two months of doxorubicin—cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol1990; 8: 1483–1496.
12.
Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet1998; 352: 930–942.
13.
OlivottoIABajdikCDPlenderleithIH: Adjuvant systemic therapy and survival after breast cancer. N Engl J Med1994; 330: 805–810.
14.
CreeIAKurbacherCM: Individualizing chemotherapy for solid tumors—is there any alternative?Anticancer Drugs1997; 8: 541–548.
15.
MaeharaYAnaiHTamadaR: The ATP assay is more sensitive than the succinate dehydrogenase inhibition test for predicting cell viability. Eur J Cancer Clin Oncol1987; 23: 273–276.
16.
O'MearaATSevinBU: Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer. Gynecol Oncol2001; 83: 334–342.
17.
NgTYNganHYChengDK: Clinical applicability of the ATP cell viability assay as a predictor of chemoresponse in platinum-resistant epithelial ovarian cancer using nonsurgical tumor cell samples. Gynecol Oncol2000; 76: 405–408.
18.
SlamonDJGodolphinWJonesLA: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science1989; 244: 707–712.
19.
SlamonDJClarkGMWongSG: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science1987; 235: 177–182.
20.
PritchardKIShepherdLEO'MalleyFP: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med2006; 354: 2103–2111.
21.
JacquemierJPenault-LlorcaFViensP: Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res1994; 14: 2773–2778.
22.
RozanSVincent-SalomonAZafraniB: No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer1998; 79: 27–33.
23.
GuarneriVBroglioKKauSW: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol2006; 24: 1037–1044.
24.
TakamuraYKobayashiHTaguchiT: Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. Int J Cancer2002; 98: 450–455.
